Celldex Therapeutics saw multiple brokerages adjust price targets this week, with Cantor Fitzgerald lowering its target to 61 while maintaining an overweight rating, and Morgan Stanley trimming its target to 40 from 44. Canaccord Genuity also reduced its target to 60 with a Buy rating, and Guggenheim raised its target to 100 as it reiterated a Buy stance, signaling diverging views on near-term upside. Other firms boosted targets or maintained favorable ratings, including Wells Fargo lifting its target to 54 and Barclays nudging to 48, though Wall Street Zen shifted to a Sell stance in some reports, underscoring ongoing debate about CLDX’s risk-reward. The stock’s price action reflected the downgrades and mixed sentiment, including a pre-market gap-down in response to Cantor’s downgrade and shifting daily averages noted in coverage. Market consensus, per MarketBeat data cited in the reports, generally leans toward a Moderate Buy with a headline target around the mid-$50s, despite notable individual target changes. Overall, investors are weighing a mix of bearish adjustments and bullish price-target revisions as Celldex remains in focus for biotechnology-focused portfolios.